EC approves Otsuka's TB drug Deltyba

The European Commission granted conditional approval to Deltyba delamanid from Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) to treat pulmonary multidrug-resistant tuberculosis (MDR-TB) in adults when alternative treatments cannot be used due to resistance or intolerance. Otsuka plans to launch the nitro-dihydro-imidazooxazole derivative in the EU in four to six weeks. ...